---
layout: default
title: 3 3 -Diindolylmethane Adenosine Triphosphate Disod
parent: 僅模型預測 (L5)
nav_order: 29
evidence_level: L5
indication_count: 0
---

# 3 3 -Diindolylmethane Adenosine Triphosphate Disod
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# 13-Ingredient Compound Formula (DIM + ATP + Homeopathic Blend): Evaluation Incomplete — No TxGNN Prediction Generated

## One-Sentence Summary

This product is a 13-ingredient formula combining a dietary supplement (3,3'-diindolylmethane, equol), energy substrate (adenosine triphosphate disodium), botanicals (Bryonia alba root, Petroselinum crispum, Sanguinaria canadensis, Homalolepis cedron seed, Strychnos ignatii seed), classical homeopathic substances (Lachesis muta venom, Sepia officinalis juice, Sulfur, Tin), and a microbial component (Alcaligenes faecalis).
The TxGNN model was **unable to generate any repurposing prediction** for this combination, as no matching DrugBank entry was found for the composite formula.
Without a prediction to evaluate, this report serves as a data-gap summary and a roadmap for further investigation.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not documented |
| Predicted New Indication | None — TxGNN prediction not available |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (No model prediction; no supporting studies identified) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why No Prediction Was Generated

The TxGNN model operates on the DrugBank knowledge graph: it requires a resolved DrugBank ID to place the drug as a node in the graph and compute repurposing scores. For this submission, no DrugBank ID could be assigned because the query string consists of 13 heterogeneous components spanning four distinct pharmacological categories:

| Category | Ingredients |
|----------|------------|
| Dietary supplement / phytochemical | 3,3'-Diindolylmethane (DIM), Equol |
| Energy substrate | Adenosine triphosphate disodium (ATP) |
| Botanical / plant-derived | Bryonia alba root, Petroselinum crispum (parsley), Sanguinaria canadensis root, Homalolepis cedron seed, Strychnos ignatii seed |
| Classical homeopathic | Lachesis muta venom, Sepia officinalis juice, Sulfur, Tin (Stannum) |
| Microbial | Alcaligenes faecalis |

Because DrugBank catalogues single molecular entities (or well-defined combinations with their own monograph), this heterogeneous multi-ingredient formula does not map to any existing node. As a result, the knowledge-graph traversal step produced zero candidates, and the deep-learning scoring step was never reached.

Additionally, no original approved indication has been documented in any regulatory database queried, which means the "From [Original Indication]" anchor for repurposing reasoning is also absent.

---

## Safety Considerations

Please refer to the package insert for safety information.

> **Note:** Several ingredients in this formula carry individual safety concerns that would require independent review before any clinical evaluation:
> - **Sanguinaria canadensis** contains sanguinarine, a toxic alkaloid; oral exposure has been linked to leukoderma and potentially to oral cancer at higher doses.
> - **Strychnos ignatii** (Ignatia) contains strychnine and brucine in its seed; therapeutic window is extremely narrow.
> - **Lachesis muta venom** contains haemotoxic and neurotoxic components; the homeopathic dilution level is critical to safety assessment.
> - **Alcaligenes faecalis** is an opportunistic pathogen; viability status and preparation method must be confirmed.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN pipeline could not be executed for this product because the multi-ingredient formula has no DrugBank ID and no documented original indication, which are both prerequisites for graph-based repurposing scoring. Without a prediction, the core analytical output of this pipeline is absent, and no evidence hierarchy can be assigned.

**To proceed, the following is needed:**

1. **Identify the finished product brand name and NDA/registration number** — determine whether this formula is registered as a single product in any jurisdiction (e.g., homeopathic OTC, dietary supplement, or biologic combination).
2. **Resolve individual DrugBank IDs per active ingredient** — DIM (DB01839), equol, and ATP disodium may each have independent entries; running TxGNN per component in parallel may yield partial predictions.
3. **Clarify the intended therapeutic indication** — the ingredient profile (EQUOL, DIM, SEPIA, LACHESIS) suggests a possible hormonal-balance or menopausal-support application, but this must be confirmed from labelling or sponsor documentation.
4. **Obtain the package insert or regulatory submission dossier** — required to assess original indication, dosing, contraindications, and the homeopathic dilution levels used.
5. **Confirm safety profile of high-risk botanical/homeopathic components** — particularly Sanguinaria canadensis, Strychnos ignatii, and Alcaligenes faecalis, before any clinical feasibility assessment.
6. **Re-run TxGNN on individual ingredients** once DrugBank IDs are confirmed, then aggregate candidate predictions at the formula level.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

